| 07.20.22 | Lilly uses 3D printing for gut-targeted delivery; Self-boosting vaccine tech emerges from MIT

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Article Download: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

The costs of drug development have escalated greatly in recent years. Read this article with expert insights on how to address compounds with difficult physicochemical properties and unfavorable absorption characteristics early on in the development process to reduce costs and attrition rates. Download now.

Today's Rundown

Lilly taps Triastek to use 3D printing for gut-targeted drug delivery MIT timed drug release tech opens door to self-boosting vaccines After rejection, Azurity gets FDA nod for liquid epilepsy drug Recipharm steps up to support development of Transpire's inhaled treatments for asthma, COPD The top 10 generic drug makers by 2021 revenue 'The Top Line' podcast: The highest paid biopharma CEOs , Merck, Seagen acquisition plus this week's headlines

Featured Story

Lilly taps Triastek to use 3D printing for gut-targeted drug delivery

By Nick Paul Taylor

Eli Lilly has identified 3D printing as a way to get drugs to specific regions of the gastrointestinal tract, leading it to team up with Triastek to work on the targeted release of molecules in the intestine.

Executive Summary: Highly Potent API Drug Product Development and Manufacturing using Micronization Technology

Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). Yet HPAPIs require specialized manufacturing and processing expertise. Learn how Catalent is addressing bioavailability and drug delivery challenges facing certain highly potent oral drugs. Download now.

MIT timed drug release tech opens door to self-boosting vaccines

By Nick Paul Taylor

From childhood immunizations to COVID-19, multiple, staggered vaccine doses are key to providing full protection against pathogens. But can the doses be delivered all at once and lie dormant until the right time? That is the question at the heart of new research from the Massachusetts Institute of Technology.

After rejection, Azurity gets FDA nod for liquid epilepsy drug

By Nick Paul Taylor

Azurity Pharmaceuticals has won FDA approval for its zonisamide oral suspension at the second time of asking, becoming the first company to secure authorization of a liquid form of the epilepsy drug in the U.S.

Recipharm steps up to support development of Transpire's inhaled treatments for asthma, COPD

By Nick Paul Taylor

Transpire Bio has tapped Recipharm to support the development of its inhaled respiratory disease drug candidates. The agreement positions Transpire to tap into Recipharm’s experience of developing and manufacturing inhaled drug products as it seeks to advance its programs toward the clinic.

The top 10 generic drug makers by 2021 revenue

By Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Angus Liu,Eric Sagonowsky

Many producers of generic drugs have struggled to achieve growth in recent years due to pricing pressures. But there are promising signs that the industry is ready for an uptick, and they were evident in 2021 as eight of the top 10 companies by generics sales realized growth.

'The Top Line' podcast: The highest paid biopharma CEOs , Merck, Seagen acquisition plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss a potential Merck acquisition of Seagen and how it could be the largest biopharma deal since 2020. Also under discussion is our special report ranking the highest paid biopharma CEOs of the year. Plus, COVID test-to-treat sites, the Biotech Sisterhood and more.

eBook: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including larger molecules and novel indications. Learn more about trends in orally and nasally inhaled therapeutics, new avenues for existing dose forms, and industry response to OINDP trends. Download Now.